25 results about "Plasmalogen" patented technology

The invention relates to a culture medium for separating and culturing stem cells in tissues and application of the culture medium. The culture medium is a basic culture medium containing genipin, plasmalogen and cell factors. The brand-new culture medium is designed, genipin, plasmalogen and cell factors are added into the basic culture medium and are integrally and synergistically matched, stem cells in tissues (such as nasal mucosa tissues) can be quickly activated, the adherence and migration speed of the stem cells is remarkably increased, proliferation of the stem cells is promoted, and cell activity is effectively maintained; the activation and separation efficiency of the stem cells is obviously improved.

This invention discloses a quantitative method for phospholipids, comprising: a sample preparation step, wherein a sample containing protein and phospholipids is mixed with Schiff reagent to obtain a sample for testing; a control sample preparation step, wherein the sample is mixed with a solvent of Schiff reagent to obtain a control sample; a measurement step, wherein the degree of a first optical property of the sample for testing and the degree of an optical property of the control sample are measured after the reaction of the aldehyde formed by the vinyl ether bond of phospholipids with Schiff reagent; and a determination step, wherein a correction degree obtained by correcting the degree of the first optical property using the degree of the optical property of the control sample is compared with the degree of a second optical property of the standard sample to determine the concentration of phospholipids in the sample, wherein the standard sample contains Schiff reagent and phospholipids of known concentration, and the degree of the second optical property is the degree of reaction of the Schiff reagent with the aldehyde formed by the vinyl ether bond of phospholipids.

To obtain a novel phospholipase D against choline-type plasmalogen.SOLUTION: Prepared is a phospholipase D comprising any of the described polypeptides: (1-1) a polypeptide having the amino acid sequence set forth in SEQ ID NO: 1; (1-2) a polypeptide having at least 85% identity with the amino acid sequence set forth in SEQ ID NO: 1, and having a hydrolytic activity to a phosphate ester bond in a choline-type plasmalogen molecule in which oleic acid is ester-bonded to the sn-2 position of a glycerol skeleton; and (1-3) a polypeptide in which one or several amino acids are added, substituted, deleted and / or inserted in the amino acid sequence set forth in SEQ ID NO: 1, and having a hydrolytic activity to a phosphate ester bond in a choline-type plasmalogen molecule.SELECTED DRAWING: Figure 3

The invention discloses application of plasmalogen in assisting in gaining muscle and reducing fat in aerobic exercise and relieving skeletal muscle and kidney injury caused by exercise, and belongs to the technical field of biological medicine. According to the invention, a model of mouse skeletal muscle and kidney injury caused by exhaustion movement is established in vivo, and skeletal muscle and kidney injury is relieved by intervention of a sea squirt phospholipid extract and sea squirt plasmalogen respectively. Skeletal muscle injury and metabolic waste entering blood of a C57BL / 6J mouse caused by continuous exhaustion exercise for 7 days greatly increase the kidney burden. The sea squirt phospholipid extract and the sea squirt plasmalogen relieve muscle and kidney injury caused by exhaustive exercise and improve exercise performance.

A protein includes an amino acid sequence selected from the group consisting of the following (a), (b), (c), and (d): (a) an amino acid sequence of SEQ ID NO:1; (b) an amino acid sequence having a sequence identity of not less than 80% to the amino acid sequence of SEQ ID NO:1; (c) an amino acid sequence of SEQ ID NO:2; and (d) an amino acid sequence having a sequence identity of not less than 80% to the amino acid sequence of SEQ ID NO:2, the protein having plasmalogen synthesis activity in a bacterium that expresses the protein.

This plasmalogen detection method comprises: a sample preparation step for mixing a Schiff's reagent and a specimen containing a plasmalogen to obtain a sample; a reaction step for reacting the plasmalogen in the sample with the Schiff's reagent; and a contact step for bringing at least some of the sample reacted in the reaction step into contact with a stationary phase containing a silica gel.

Provided is an α -synuclein phagocytosis promoter comprising plasmalogen or a compound represented by formula (I), a racemic body thereof, or a salt thereof. [In formula (I): X represents a carbon atom or an oxygen atom; R1 represents a saturated aliphatic hydrocarbon group that optionally includes a ring structure; R2 represents a saturated or unsaturated aliphatic hydrocarbon group that has 10-30 carbon atoms and that optionally has a substituent which is an alkyl group having 1-4 carbon atoms or an alkoxy group having 1-4 carbon atoms; carbon atoms of the glycerol skeleton optionally have substituents; and R3 is represented by formula (A) that optionally has a substituent, where * represents the oxygen atom bound to R3.]

The invention provides a method for preparing a composition capsule containing a sea squirt extract, DHA and NMN, and relates to the technical field of health-care food. The composition capsule is composed of the sea squirt extract, free docosahexaenoic acid, nicotinamide mononucleotide and vitamin E. The composition comprises the following components in parts by weight: 14-20 parts of the sea squirt extract, 20-40 parts of the free docosahexaenoic acid, 40-53 parts of the nicotinamide mononucleotide and 0.2-2 parts of the vitamin E. The plasmalogen in the sea squirt extract can improve the function of a cell membrane in brain cells and improve the immunity of the brain cells. DHA has the effect of promoting formation and development of brain cells, NMN is utilized for promoting synthesis and release of neurotransmitters to improve the function stability of a nervous system, vitamin E serves as an antioxidant and an anti-inflammatory agent to enhance nerve protection, and the composition capsule has the synergistic effect, so that the brain function is remarkably enhanced, brain aging is delayed, and the effect of improving the brain function is achieved. The senile dementia is effectively prevented and improved.

This disclosure relates to synthetic methods of making bioactive in vivo precursors to plasmalogen compounds and salts thereof and to making plasmalogens and their derivatives and salts thereof. This disclosure also relates to chemical precursors to bioactive compounds and salts thereof. This disclosure further relates to compositions comprising one or more compounds of this disclosure and the use of such compositions in preparing compounds useful in methods of treating diseases and conditions that are beneficially treated by administering plasmalogens or their derivatives or precursors that are transformed in vivo to plasmalogens.

The invention belongs to the technical field of biological medicines, and particularly relates to application of EPA (eicosapentaenoic acid) plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy, which is characterized by treating diabetic nephropathy mouse models induced by high fat diet and streptozotocin and having insulin resistance and hyperglycemia accompanied by kidney lipid accumulation and glomerular filtration rate reduction, and particularly relates to application of EPA plasmalogen in preparation of medicines for improving or preventing diabetic nephropathy. The treatment effect of the EPA plasmalogen on the diabetic nephropathy is observed; results show that the EPA plasmalogen has obvious effects of improving kidney functions and kidney ectopic lipid deposition on diabetic nephropathy mice induced by high fat diet and streptozotocin, and also has the effects of reducing blood sugar, improving blood fat, reducing insulin resistance and the like. The EPA plasmalogen is used for intervening the diabetic nephropathy for the first time, and an important basis is provided for clinically treating the diabetic nephropathy by using the EPA plasmalogen.

This disclosure relates to synthetic methods of making bioactive in vivo precursors to plasmalogen compounds and salts thereof and to making plasmalogens and their derivatives and salts thereof. This disclosure also relates to chemical precursors to bioactive compounds and salts thereof. This disclosure further relates to compositions comprising one or more compounds of this disclosure and the use of such compositions in preparing compounds useful in methods of treating diseases and conditions that are beneficially treated by administering plasmalogens or their derivatives or precursors that are transformed in vivo to plasmalogens.

Disclosed is a muscle enhancer which contains plasmalogen as an active ingredient.

The invention discloses application of plasmalogen and plasmalogen acyl ethanolamine in preparation of a product for improving premature ovarian failure. The product is food, a health care product, a dietary supplement, a fetal animal feed or a fetal animal feed additive. The invention also discloses a product for improving premature ovarian failure. The effective components of the product comprise the plasmalogen and the plasmalogen acyl ethanolamine. The plasmalogen and the plasmalogen acyl ethanolamine can improve the estradiol level in the body and inhibit the abnormal increase of follicle stimulating hormone in the body.

This disclosure relates to methods of using certain precursor compounds such as lysoalkylphosphatidylcholines, (LPC(O)s) to increase the levels of plasmalogens in the subject to provide improved health outcomes. More specifically, this disclosure relates to the use of the precursor compounds to treat liver diseases and controlling weight.

This method for quantifying plasmalogens comprises: a measurement sample preparation step for mixing a Schiff reagent with a specimen containing protein and plasmalogens to obtain a measurement sample; a control sample preparation step for mixing the specimen with a solvent of the Schiff reagent to obtain a control sample; a measurement step for measuring the extent of a first optical property of the measurement sample, the first optical property being obtained by reacting the Schiff reagent with an aldehyde generated from vinyl ether bonds of the plasmalogens, and measuring the extent of the optical property of the control sample; and a determination step for determining the concentration of plasmalogens in the specimen by comparing the correction extent, that is the extent to which the extent of the first optical property has been corrected by the extent of the optical property of the control sample, with the extent of a second optical property of a standard sample containing the Schiff reagent and a known concentration of plasmalogens, the second optical property being the optical property after the Schiff reagent has been reacted with the aldehyde generated from the vinyl ether bonds of the plasmalogens.

This invention discloses an adiponectin enhancer, which contains phospholipid acetal as an active ingredient.

It is a composition for enhancing immune function, or a composition for activating natural killer cells, comprising plasmalogen.

A method for promoting collagen production, which includes administering to a human a composition containing plasmalogen. The plasmalogen can be a plasmalogen extracted from animal tissues. The composition containing the plasmalogen can be administered to the human as an oral agent or as a parenteral agent. Parenteral agents include external agent and injection agents.

The invention belongs to the technical field of medicine research, and particularly relates to application of plasmalogen in preparation of a medicine for treating intestinal vascular barrier injury. Tests prove that the plasmalogen can improve intestinal flora disorder induced by high fat diet and prevent intestinal bacteria from invading intestinal barriers, so that the integrity of intestinal vascular barriers is protected.

The invention relates to engineering saccharomycetes for synthesizing plasmalogen as well as a construction method and application thereof, and belongs to the technical field of microbial engineering, chassis cells of the engineering saccharomycetes are yarrowia lipolytica, and CarF genes of aldolase are integrated at URA sites of yarrowia lipolytica genes. The nucleotide sequence of the gene CarF is shown as SEQ ID NO: 1 or a degenerate sequence of the SEQ ID NO: 1, or a base sequence having more than 80% of sequence identity with the SEQ ID NO: 1 and a corresponding amino acid sequence of the base sequence. According to the engineering saccharomycetes PG01, the yield of plasmalogen is 0.21 mg / g protein and is increased by one time compared with the yield of wild saccharomycetes.

The invention discloses application of mussel plasmalogen in preparation of a product for improving activity of lithocholic acid synthase. The mussel plasmalogen comprises mussel plasmalogen phosphatidylethanolamine and / or mussel plasmalogen phosphatidylserine. The mussel plasmalogen comprises mussel plasmalogen phosphatidylethanolamine and The mussel plasmalogen promotes the biosynthesis of lithocholic acid by enhancing the activity of lithocholic acid synthetase, significantly reduces the content of a lithocholic acid synthesis precursor and significantly improves the lithocholic acid level.

Provided is an α -synuclein phagocytosis promoter comprising plasmalogen or a compound represented by formula (I), a racemic body thereof, or a salt thereof. [In formula (I): X represents a carbon atom or an oxygen atom; R1 represents a saturated aliphatic hydrocarbon group that optionally includes a ring structure; R2 represents a saturated or unsaturated aliphatic hydrocarbon group that has 10-30 carbon atoms and that optionally has a substituent which is an alkyl group having 1-4 carbon atoms or an alkoxy group having 1-4 carbon atoms; carbon atoms of the glycerol skeleton optionally have substituents; and R3 is represented by formula (A) that optionally has a substituent, where * represents the oxygen atom bound to R3.]

The present invention provides a method for fluorescently labeling plasmalogens, which method comprises: contacting a compound represented by formula (I) or a stereoisomer, tautomer or salt thereof with a substrate to be labeled, wherein the substrate to be labeled comprises at least one vinyl ether bond. The method of the present invention can selectively label plasmalogens without interference from other lipids. This fluorescent labeling method can be combined with simple instrument devices such as high performance liquid chromatography and fluorescence detector as an accurate fluorescence analysis method for plasmalogens, and is used for rapid analysis and screening of plasmalogens in blood lipids. This method has high accuracy and low cost in detecting plasmalogens in blood lipids.

The present invention provides a brain plasmalogen increasing agent comprising a compound represented by formula (I) (in the formula, X represents a carbon atom or an oxygen atom, R1 represents a saturated aliphatic hydrocarbon group which may contain a cyclic structure, R2 represents a saturated or unsaturated aliphatic hydrocarbon group which may have a substituent and has 10 to 30 carbon atoms), a racemate thereof, or a salt of the compound or the racemate, and a salt of the racemate or the salt of the compound represented by formula (I) (in the formula, X represents a carbon atom or an oxygen atom, R1 represents a saturated aliphatic hydrocarbon group which may have a cyclic structure). The substituent group is an alkyl group with a carbon atom number of 1-4 or an alkoxy group with a carbon atom number of 1-4.

To provide a method that enables long-term stable preservation of plasmalogen when plasmalogen is used in combination with ginkgo biloba extract.SOLUTION: A composition comprising plasmalogen, ginkgo biloba extract, and arginine and / or lysine, wherein the pH upon tenfold dilution with ion-exchanged water is in the range of 3.4 to 5.SELECTED DRAWING: None